{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:51:34Z","timestamp":1753890694465,"version":"3.41.2"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Genetic obesity, including syndromic and non-syndromic forms, represents a minority of cases compared to essential obesity but gene dysregulations lead to complex clinical conditions that make their management particularly difficult. Among them, Beckwith-Wiedemann syndrome (BWS) is a multisystem human genomic imprinting disorder characterized by overgrowth. We describe the first case of liraglutide treatment in an 18-year-old boy patient affected by BWS complicated by macroglossia, cryptorchidism, nephroblastoma, organomegaly, microscopic lymphocytic colitis, pharmacologically treated arterial hypertension, obesity, and obstructive sleep apnea syndrome. He presented a normal cognitive development. Body mass index at the time of first transition visit in the adult endocrinology department at the age of 18-years-old was 40.6 kg\/m<jats:sup>2<\/jats:sup> without glucose metabolism impairment. Lifestyle interventions failed because of poor compliance. During 20 months of 3.0 mg liraglutide treatment, a weight loss of 19\u00a0kg (\u221213.3%) and BMI reduction of 6.8 points were registered without side effects. To date, liraglutide treatment was effective on obesity in 7 subjects with Prader Willy Syndrome and 14 with melanocortin-4 receptor mutations. The efficacy of liraglutide in BWS could be related to a crosstalk among glucagon-like peptide (GLP)-1 system, mechanisms related to the cyclin-dependent kinase inhibitor 1C (CDKN1C), and dopamine mesolimbic circuit. Clinical trials aiming at a tailored medicine in genetic obesity are needed.<\/jats:p>","DOI":"10.3389\/fendo.2021.687918","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T06:47:31Z","timestamp":1624344451000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Liraglutide for Weight Management in Beckwith-Wiedemann Syndromic Obesity"],"prefix":"10.3389","volume":"12","author":[{"given":"Marina","family":"Caputo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Daffara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simonetta","family":"Bellone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Mancioppi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Marzullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Aimaretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Prodam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60460-8","article-title":"Global, Regional, and National Prevalence of Overweight and Obesity in Children and Adults During 1980\u20132013: A Systematic Analysis for the Global Burden of Disease Study 2013","volume":"384","author":"Ng","year":"2014","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijerph14040435","article-title":"Economic Burden of Obesity: A Systematic Literature Review","volume":"14","author":"Tremmel","year":"2017","journal-title":"Int J Environ Res Public Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-0363","article-title":"Mechanisms in Endocrinology Update on Treatments for Patients With Genetic Obesity","volume":"163","author":"Poitou","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fgene.2020.563718","article-title":"Preclinical and Clinical Epigenetic-Based Reconsideration of Beckwith-Wiedemann Syndrome","volume":"11","author":"Papulino","year":"2020","journal-title":"Front Genet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2014-307097","article-title":"Underdiagnosed Beckwith-Wiedemann Syndrome Among Early Onset Obese Children","volume":"99","author":"Martos-Moreno","year":"2014","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"B6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ejmg.2018.05.014","article-title":"Beckwith Wiedemann Syndrome: A Population-Based Study on Prevalence, Prenatal Diagnosis, Associated Anomalies and Survival in Europe","volume":"61","author":"Barisic","year":"2018","journal-title":"Eur J Med Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.166","article-title":"Clinical and Molecular Diagnosis, Screening and Management of Beckwith\u2013Wiedemann Syndrome: An International Consensus Statement","volume":"14","author":"Brioude","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00562","article-title":"Diagnosis and Management of Beckwith-Wiedemann Syndrome","volume":"7","author":"Wang","year":"2019","journal-title":"Front Pediatr"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.61301","article-title":"Phenotype Evolution and Health Issues of Adults With Beckwith-Wiedemann Syndrome","volume":"179","author":"Gazzin","year":"2019","journal-title":"Am J Med Genet Part A"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/ng1410","article-title":"Microdeletions in the Human H19 DMR Result in Loss of IGF2 Imprinting and Beckwith-Wiedemann Syndrome","volume":"36","author":"Sparago","year":"2004","journal-title":"Nat Genet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.amjmed.2010.11.002","article-title":"Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications","volume":"124","author":"Nauck","year":"2011","journal-title":"Am J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2011.8.339","article-title":"Therapy for Obesity Based on Gastrointestinal Hormones","volume":"8","author":"Bagger","year":"2011","journal-title":"Rev Diabetes Stud"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.7602","article-title":"Association of Pharmacological Treatments for Obesity Withweight Loss and Adverse Events a Systematic Review and Meta-Analysis","volume":"315","author":"Khera","year":"2016","journal-title":"JAMA - J Am Med Assoc"},{"key":"B14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 Mg of Liraglutide in Weight Management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2575","article-title":"Use of GLP-1 Receptor Agonists in Prader-Willi Syndrome: Report of Six Cases","volume":"37","author":"Fintini","year":"2014","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2020.25.1.52","article-title":"Successful Rapid Weight Reduction and the Use of Liraglutide for Morbid Obesity in Adolescent Prader-Willi Syndrome","volume":"25","author":"Kim","year":"2020","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.ej12-0074","article-title":"The Glucagon-Like Peptide-1 Analog Liraglutide Suppresses Ghrelin and Controls Diabetes in a Patient With Prader-Willi Syndrome","volume":"59","author":"Senda","year":"2012","journal-title":"Endocr J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2011.03280.x","article-title":"Liraglutide Therapy in Prader-Willi Syndrome","volume":"28","author":"Cyganek","year":"2011","journal-title":"Diabetes Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cmet.2018.05.008","article-title":"Patients With Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated With a Glucagon-Like Peptide-1 Receptor Agonist","volume":"28","author":"Iepsen","year":"2018","journal-title":"Cell Metab"},{"key":"B20","unstructured":"Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1101\/gad.9.6.639","article-title":"Cloning of p57KIP2, a Cyclin-Dependent Kinase Inhibitor With Unique Domain Structure and Tissue Distribution","volume":"9","author":"Lee","year":"1995","journal-title":"Genes Dev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1101\/gad.9.6.650","article-title":"p57KIP2, a Structurally Distinct Member of the P21cip1 Cdk Inhibitor Family, Is a Candidate Tumor Suppressor Gene","volume":"9","author":"Matsuoka","year":"1995","journal-title":"Genes Dev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M609944200","article-title":"The Cyclin-Dependent Kinase Inhibitors p57 and p27 Regulate Neuronal Migration in the Developing Mouse Neocortex","volume":"282","author":"Itoh","year":"2007","journal-title":"J Biol Chem"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2635658100","article-title":"p57(Kip2) Cooperates With Nurr1 in Developing Dopamine Cells","volume":"100","author":"Joseph","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/bhq254","article-title":"The Cyclin-Dependent Kinase Inhibitor p57Kip2 Regulates Cell Cycle Exit, Differentiation, and Migration of Embryonic Cerebral Cortical Precursors","volume":"21","author":"Tury","year":"2011","journal-title":"Cereb Cortex"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/dneu.20680","article-title":"Patterns of p57Kip2 Expression in Embryonic Rat Brain Suggest Roles in Progenitor Cell Cycle Exit and Neuronal Differentiation","volume":"69","author":"Ye","year":"2009","journal-title":"Dev Neurobiol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddw357","article-title":"Behavioural Abnormalities in a Novel Mouse Model for Silver Russell Syndrome","volume":"25","author":"McNamara","year":"2016","journal-title":"Hum Mol Genet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/gbb.12422","article-title":"Dopaminergic and Behavioural Changes in a Loss-of-Imprinting Model of Cdkn1c","volume":"17","author":"McNamara","year":"2018","journal-title":"Genes Brain Behav"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s0306-4522(96)00434-4","article-title":"Distribution of Glucagon-Like Peptide-1 and Other Preproglucagon-Derived Peptides in the Rat Hypothalamus and Brainstem","volume":"77","author":"Larsen","year":"1997","journal-title":"Neuroscience"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/en.2014-1675","article-title":"Expression and Distribution of Glucagon-Like Peptide-1 Receptor mRNA, Protein and Binding in the Male Nonhuman Primate (Macaca Mulatta) Brain","volume":"156","author":"Heppner","year":"2015","journal-title":"Endocrinology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-3874-y","article-title":"GLP-1 Receptors Exist in the Parietal Cortex, Hypothalamus and Medulla of Human Brains and the GLP-1 Analogue Liraglutide Alters Brain Activity Related to Highly Desirable Food Cues in Individuals With Diabetes: A Crossover, Randomised, Placebo-Controlled","volume":"59","author":"Farr","year":"2016","journal-title":"Diabetologia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.06.062","article-title":"Endogenous Glucagon-Like Peptide-1 Suppresses High-Fat Food Intake by Reducing Synaptic Drive Onto Mesolimbic Dopamine Neurons","volume":"12","author":"Wang","year":"2015","journal-title":"Cell Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2014.09.001","article-title":"CDKN1C Mutations: Two Sides of the Same Coin","volume":"20","author":"Eggermann","year":"2014","journal-title":"Trends Mol Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4652(199709)172:3<275::AID-JCP1>3.0.CO;2-L","article-title":"Novel Signal Transduction and Peptide Specificity of Glucagon-Like Peptide Receptor in 3T3-L1 Adipocytes","volume":"172","author":"Montrose-Rafizadeh","year":"1997","journal-title":"J Cell Physiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1990.258.3.E534","article-title":"IGF-II Receptors and IGF-II-Stimulated Glucose Transport in Human Fat Cells","volume":"258","author":"Sinha","year":"1990","journal-title":"Am J Physiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0589","article-title":"Effects of Liraglutide on Weight Loss, Fat Distribution, and B-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes","volume":"40","author":"Santilli","year":"2017","journal-title":"Diabetes Care"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2337\/db09-0063","article-title":"Glucagon-Like Peptide-1 Protects \u03b2-Cells Against Apoptosis by Increasing the Activity of an Igf-2\/Igf-1 Receptor Autocrine Loop","volume":"58","author":"Cornu","year":"2009","journal-title":"Diabetes"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2018.8475","article-title":"Liraglutide Inhibits the Proliferation and Promotes the Apoptosis of MCF-7 Human Breast Cancer Cells Through Downregulation of microRNA-27a Expression","volume":"17","author":"Zhao","year":"2018","journal-title":"Mol Med Rep"},{"key":"B39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejmg.2015.11.008","article-title":"Recommendations of the Scientific Committee of the Italian Beckwith-Wiedemann Syndrome Association on the Diagnosis, Management and Follow-Up of the Syndrome","volume":"59","author":"Mussa","year":"2016","journal-title":"Eur J Med Genet"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.687918\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T06:47:34Z","timestamp":1624344454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.687918\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":39,"alternative-id":["10.3389\/fendo.2021.687918"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.687918","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"article-number":"687918"}}